<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The success of allogeneic bone marrow transplantation (allo-BMT) in children with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is mainly affected by relapse </plain></SENT>
<SENT sid="1" pm="."><plain>The role of additional immunotherapy for pediatric patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> relapsing after allo-BMT remains to be established </plain></SENT>
<SENT sid="2" pm="."><plain>Because immunotherapy is generally more effective for patients who bear a low <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden, monitoring of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual diseases</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) is essential for early diagnosis at molecular relapse </plain></SENT>
<SENT sid="3" pm="."><plain>We report here that a patient with relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> after allo-BMT was successfully treated by the rapid discontinuation of immunosuppressive therapy at molecular relapse while monitoring <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> (WT1) gene expression levels </plain></SENT>
<SENT sid="4" pm="."><plain>Quantitative analysis of WT1 gene expression appeared to be a useful tool to monitor <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> in the present case </plain></SENT>
</text></document>